Current stage?-Stage I - Page 2 of 24 Posts on Medivizor
Navigation Menu

Current stage?-Stage I Posts on Medivizor

Evaluating hypofractionated radiotherapy after prostate surgery in patients with prostate cancer.

Evaluating hypofractionated radiotherapy after prostate surgery in patients with prostate cancer.

Posted by on Jul 21, 2021 in Prostate cancer | 0 comments

In a nutshell This study investigated the outcomes of hypofractionated intensity-modulated radiation therapy (H-IMRT) to the prostate bed in patients with localized prostate cancer after prostate surgery. The data showed that H-IMRT after prostate surgery was safe and well-tolerated in these patients. Some background Localized prostate cancer...

Read More

What is the best timing for chemotherapy after surgery in patients with early-stage breast cancer?

What is the best timing for chemotherapy after surgery in patients with early-stage breast cancer?

Posted by on Jul 11, 2021 in Breast cancer | 0 comments

In a nutshell This study looked at the timing of chemotherapy (CT) after surgery in the treatment of early breast cancer (BC). The authors found that CT given within 31 days after surgery may improve survival in patients with triple-negative (TN) BC.  Some background BC is one of the most common types of cancer found in women. There are...

Read More

Evaluating the effectiveness and safety of radiofrequency ablation for breast cancer smaller than 2 cm.

Evaluating the effectiveness and safety of radiofrequency ablation for breast cancer smaller than 2 cm.

Posted by on Jul 11, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of radiofrequency ablation (RFA) for breast cancer (BC) smaller than 2 cm. The data showed that RFA was safe and effective in these patients. Some background Radiofrequency ablation (RFA) is a medical procedure where pieces of tissue are removed using the heat that is produced from an...

Read More

Evaluating the effectiveness of salvage radiotherapy for recurrence after prostate surgery in patients with localized prostate cancer.

Evaluating the effectiveness of salvage radiotherapy for recurrence after prostate surgery in patients with localized prostate cancer.

Posted by on Jun 30, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness of salvage radiotherapy (RT) in patients with recurrence of prostate cancer (PCa) after prostate surgery. The study found that salvage RT was effective in the management of PCa recurrence with manageable side effects. Some background Localized prostate cancer (PCa) is a form of cancer that...

Read More

FOLFIRINOX before pre-surgery treatment can improve the outcomes of patients with rectal cancer

FOLFIRINOX before pre-surgery treatment can improve the outcomes of patients with rectal cancer

Posted by on Jun 6, 2021 in Colorectal cancer | 0 comments

In a nutshell The aim of this study was to investigate FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, and fluorouracil) before pre-surgery chemoradiotherapy (CRT) for patients with rectal cancer (RC). The study found that FOLFIRINOX given before CRT and surgery improved the outcomes of these patients. Some background RC can be treated with...

Read More

Does radiotherapy with electrons boost during surgery reduce the risk of breast cancer recurrence?

Does radiotherapy with electrons boost during surgery reduce the risk of breast cancer recurrence?

Posted by on May 16, 2021 in Breast cancer | 0 comments

In a nutshell The authors investigated whether intra-operative electron radiotherapy (IOERT) boost reduces breast cancer recurrence compared to standard radiotherapy. They found that IOERT slightly reduced cancer recurrence compared to standard external beam radiotherapy (EBRT). Some background Breast cancer is the most commonly diagnosed...

Read More

Can stereotactic body radiotherapy can be used as an alternative to minimal invasive surgery for early-stage non-small cell lung cancer?

Can stereotactic body radiotherapy can be used as an alternative to minimal invasive surgery for early-stage non-small cell lung cancer?

Posted by on Apr 10, 2021 in Lung cancer | 0 comments

In a nutshell This article compared the use of video-assisted thoracoscopic lobectomy (VATL) versus stereotactic body radiotherapy (SBRT) for the treatment of early-stage non-small cell lung cancer (NSCLC). The authors found that SBRT could provide an alternative treatment option for these patients.  Some background Early-stage NSCLC is...

Read More

Should ipilimumab and nivolumab treatment be considered before surgery in operable non-small cell lung cancer?

Should ipilimumab and nivolumab treatment be considered before surgery in operable non-small cell lung cancer?

Posted by on Apr 4, 2021 in Lung cancer | 0 comments

In a nutshell This trial was carried out to look at the effectiveness of nivolumab (Opdivo) and nivolumab plus ipilimumab (Yervoy) as neoadjuvant therapy (NAT; treatment before surgery) in treating operable non-small cell lung cancer (NSCLC). The authors found that ipilimumab and nivolumab treatment before surgery provides better...

Read More

Evaluating the final effectiveness and safety outcomes of neratinib in patients with early stage HER2+/HR+ breast cancer.

Evaluating the final effectiveness and safety outcomes of neratinib in patients with early stage HER2+/HR+ breast cancer.

Posted by on Apr 4, 2021 in Breast cancer | 0 comments

In a nutshell This study reported the final effectiveness and safety outcomes of neratinib treatment in patients with early-stage HER2+/HR+ breast cancer. The data showed that neratinib significantly improved invasive disease-free survival in these patients who initiated treatment within 1 year of trastuzumab-based therapy. Some background...

Read More

Evaluating patient-reported outcomes with enzalutamide in the treatment of non-metastatic castration-resistant prostate cancer

Evaluating patient-reported outcomes with enzalutamide in the treatment of non-metastatic castration-resistant prostate cancer

Posted by on Mar 28, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated patient-reported outcomes in men with non-metastatic castration-resistant prostate cancer (CRPC) when treated with either enzalutamide (Xtandi) or a placebo. The data showed that enzalutamide treatment delayed the time until pain progression and improved the quality of life of patients compared to a placebo. Some...

Read More